Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Pharmaceuticals / Research and Development
The Medicines Company Discontinues Development of MDCO-216
Nov. 14, 2016
The Medicines Company has terminated the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.
Data from the pilot trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing